journal articles
VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIES
D.R. Scrase, N. Budhwar
J Prev Alz Dis 2023;3(10):336-338
The recent conflicting recommendations on coverage and use of monoclonal antibody treatments for Alzheimer’s Disease (AD) in the United States provide an opportunity to better define the concepts of safety, efficacy, reasonableness, and necessity. The translation of current science into clinical practice may require additional studies that enroll patients like those seen by primary care providers. Regarding recently published clinical trials as a step forward toward an AD cure is critical, as is wide collaboration between researchers and clinicians, and public and private sectors, to ensure that new effective therapies can be easily provided in clinical practice settings.
CITATION:
D.R. Scrase ; N. Budhwar ; (2023): Viewpoint: Balancing the Conflicting Goals for Treatment of Alzheimer’s Disease with Monoclonal Antibodies. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2023.71